{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:59:47Z","timestamp":1770145187607,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The objective of the present study was to perform a quantitative analysis of cancer stem cell (CSC) marker expression in ovarian carcinoma effusions. The clinical role of SSEA1 in metastatic high-grade serous carcinoma (HGSC) was additionally analyzed. CD133, Nanog, SOX2, Oct3\/4, SSEA1, and SSEA4 protein expressions were quantitatively analyzed using flow cytometry (FCM) in 24 effusions. SSEA1 expression by immunohistochemistry was analyzed in 384 HGSC effusions. Highly variable expression of CSC markers by FCM was observed, ranging from 0 to 78% of Ber-EP4-positive cells in the case of CD133, with the largest number of negative specimens seen for SSEA4. SSEA1 expression by immunohistochemistry was found in HGSC cells in 336\/384 (89%) effusions, most commonly focally (&lt;\u20095% of cells). SSEA1 was overexpressed in post-chemotherapy disease recurrence specimens compared with chemo-na\u00efve HGSC effusions tapped at diagnosis (<jats:italic>p<\/jats:italic>\u2009=\u20090.029). In univariate survival analysis, higher SSEA1 expression was significantly associated with poor overall survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.047) and progression-free survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.018), though it failed to retain its prognostic role in Cox multivariate survival analysis in which it was analyzed with clinical parameters (<jats:italic>p<\/jats:italic>\u2009=\u20090.059 and<jats:italic>p<\/jats:italic>\u2009=\u20090.111 for overall and progression-free survival, respectively). In conclusion, CSC markers are variably expressed in ovarian carcinoma effusions. SSEA1 expression is associated with disease progression and poor survival in metastatic HGSC. Silencing this molecule may have therapeutic relevance in this cancer.<\/jats:p>","DOI":"10.1007\/s00428-020-02850-4","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T20:03:39Z","timestamp":1590782619000},"page":"677-685","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma"],"prefix":"10.1007","volume":"477","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3332-8427","authenticated-orcid":false,"given":"Ben","family":"Davidson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arild","family":"Holth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiep Phuc","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"key":"2850_CR1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424","journal-title":"CA Cancer J Clin"},{"key":"2850_CR2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3322\/caac.21559","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM (2019) Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin 69:280\u2013304","journal-title":"CA Cancer J Clin"},{"key":"2850_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12943-017-0638-3","volume":"16","author":"M Lupia","year":"2017","unstructured":"Lupia M, Cavallaro U (2017) Ovarian cancer stem cells: still an elusive entity? Mol Cancer 16:64","journal-title":"Mol Cancer"},{"key":"2850_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yexcr.2017.10.018","volume":"362","author":"T Muinao","year":"2018","unstructured":"Muinao T, Deka Boruah HP, Pal M (2018) Diagnostic and prognostic biomarkers in ovarian cancer and the potential roles of cancer stem cells - an updated review. Exp Cell Res 362:1\u201310","journal-title":"Exp Cell Res"},{"key":"2850_CR5","volume-title":"Serous effusions - etiology, diagnosis, prognosis and therapy","author":"B Davidson","year":"2018","unstructured":"Davidson B (2018) Ovarian Carcinoma. In: Davidson B, Firat P, Michael CW (eds) Serous effusions - etiology, diagnosis, prognosis and therapy, 2nd edn. Springer, London","edition":"2"},{"key":"2850_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1586\/14737159.2016.1156532","volume":"16","author":"B Davidson","year":"2016","unstructured":"Davidson B (2016) Recently identified drug resistance biomarkers in ovarian cancer. Expert Rev Mol Diagn 16:569\u2013578","journal-title":"Expert Rev Mol Diagn"},{"key":"2850_CR7","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fonc.2013.00256","volume":"3","author":"N Ahmed","year":"2013","unstructured":"Ahmed N, Stenvers KL (2013) Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol 3:256","journal-title":"Front Oncol"},{"key":"2850_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.humpath.2016.08.005","volume":"58","author":"B Davidson","year":"2016","unstructured":"Davidson B (2016) CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells. Hum Pathol 58:123\u2013127","journal-title":"Hum Pathol"},{"key":"2850_CR9","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.humpath.2010.10.025","volume":"42","author":"TE Hetland","year":"2011","unstructured":"Hetland TE, Hellesylt E, Fl\u00f8renes VA, Trop\u00e9 C, Davidson B, K\u00e6rn J (2011) Class III \u03b2-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hum Pathol 42:1019\u20131026","journal-title":"Hum Pathol"},{"key":"2850_CR10","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.ygyno.2019.03.099","volume":"153","author":"M Sherman-Samis","year":"2019","unstructured":"Sherman-Samis M, Onallah H, Holth A, Reich R, Davidson B (2019) SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma. Gynecol Oncol 153:651\u2013660","journal-title":"Gynecol Oncol"},{"key":"2850_CR11","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/cyto.b.20172","volume":"72B","author":"HP Dong","year":"2007","unstructured":"Dong HP, Holth A, Berner A, Davidson B, Risberg B (2007) Flow cytometric immunphenotyping of epithelial cancer cells in effusions- technical considerations and pitfalls. Cytometry B Clin Cytom 72B:332\u2013343","journal-title":"Cytometry B Clin Cytom"},{"key":"2850_CR12","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s10719-016-9706-y","volume":"34","author":"ME Breimer","year":"2017","unstructured":"Breimer ME, S\u00e4lj\u00f6 K, Barone A, Teneberg S (2017) Glycosphingolipids of human embryonic stem cells. Glycoconj J 34:713\u2013723","journal-title":"Glycoconj J"},{"key":"2850_CR13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s10719-016-9684-0","volume":"34","author":"K Handa","year":"2017","unstructured":"Handa K, Hakomori SI (2017) Changes of glycoconjugate expression profiles during early development. Glycoconj J 34:693\u2013699","journal-title":"Glycoconj J"},{"key":"2850_CR14","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00441-013-1677-8","volume":"354","author":"M Stimpfel","year":"2013","unstructured":"Stimpfel M, Skutella T, Cvjeticanin B et al (2013) Isolation, characterization and differentiation of cells expressing pluripotent\/multipotent markers from adult human ovaries. Cell Tissue Res 354:593\u2013607","journal-title":"Cell Tissue Res"},{"key":"2850_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13048-017-0306-7","volume":"10","author":"N Kenda Suster","year":"2017","unstructured":"Kenda Suster N, Smrkolj S, Virant-Klun I (2017) Putative stem cells and epithelial-mesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers. J Ovarian Res 10:11","journal-title":"J Ovarian Res"},{"key":"2850_CR16","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13058-015-0652-6","volume":"17","author":"A Aloia","year":"2015","unstructured":"Aloia A, Petrova E, Tomiuk S et al (2015) The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features. Breast Cancer Res 17:146","journal-title":"Breast Cancer Res"},{"key":"2850_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/modpathol.3800471","volume":"19","author":"NG Ord\u00f3\u00f1ez","year":"2006","unstructured":"Ord\u00f3\u00f1ez NG (2006) The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol 19:34\u201348","journal-title":"Mod Pathol"},{"key":"2850_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/jb\/mvm031","volume":"141","author":"M Iwamori","year":"2007","unstructured":"Iwamori M, Iwamori Y, Kubushiro K, Ishiwata I, Kiguchi K (2007) Characteristic expression of Lewis-antigenic glycolipids in human ovarian carcinoma-derived cells with anticancer drug-resistance. J Biochem 141:309\u2013317","journal-title":"J Biochem"},{"key":"2850_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s004280050393","volume":"435","author":"B Davidson","year":"1999","unstructured":"Davidson B, Risberg B, Kristensen G et al (1999) Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers. Virchows Arch 435:43\u201349","journal-title":"Virchows Arch"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-020-02850-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-020-02850-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-020-02850-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T18:13:32Z","timestamp":1696184012000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-020-02850-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["2850"],"URL":"https:\/\/doi.org\/10.1007\/s00428-020-02850-4","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,29]]},"assertion":[{"value":"23 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Regional Committee for Medical Research Ethics in Norway.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}